The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?

Gastrointest Endosc Clin N Am. 2019 Jul;29(3):405-419. doi: 10.1016/j.giec.2019.03.001. Epub 2019 Apr 12.

Authors

Sujaata Dwadasi¹, Amanda Israel¹, David T Rubin²

Affiliations

¹ Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S. Maryland Avenue, MC 4076, Chicago, IL 60637, USA.
² Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S. Maryland Avenue, MC 4076, Chicago, IL 60637, USA. Electronic address: drubin@medicine.bsd.uchicago.edu.

PMID: 31078244
DOI: 10.1016/j.giec.2019.03.001

No abstract available

Keywords: Anti–tumor necrosis factor therapy; Biologics; Inflammatory bowel disease; Therapeutic drug monitoring.

Publication types

Review

MeSH terms

Adalimumab / therapeutic use
Antibodies, Monoclonal / therapeutic use*
Biosimilar Pharmaceuticals / therapeutic use
Drug Therapy, Combination
Gastrointestinal Agents / therapeutic use*
Humans
Immunosuppressive Agents / therapeutic use
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / etiology
Inflammatory Bowel Diseases / immunology
Inflammatory Bowel Diseases / pathology
Infliximab / therapeutic use
Piperidines / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / therapeutic use
Pyrroles / therapeutic use
Severity of Illness Index
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Biosimilar Pharmaceuticals
Gastrointestinal Agents
Immunosuppressive Agents
Piperidines
Protein Kinase Inhibitors
Pyrimidines
Pyrroles
Tumor Necrosis Factor-alpha
tofacitinib
Infliximab
Adalimumab